<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00509613</url>
  </required_header>
  <id_info>
    <org_study_id>UMCNONCO 2006_01</org_study_id>
    <secondary_id>2006-006454-10</secondary_id>
    <nct_id>NCT00509613</nct_id>
  </id_info>
  <brief_title>Phase 1 Study With Sorafenib and Sirolimus</brief_title>
  <official_title>Phase 1 Dose Escalation Study With Sorafenib in Combination With Sirolimus in Patients With Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to identify the recommended dose of sorafenib and sirolimus for&#xD;
      combination therapy in subsequent phase 2 trials.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>identify the recommended doses for the combination of sorafenib and sirolimus for subsequent phase II studies</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>to determine the safety profile of the combination therapy of sorafenib with sirolimus</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to determine, if possible, the Maximum Tolerated Dose (MTD) of sorafenib and sirolimus in combination therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to analyze pharmacokinetic PK profiles (AUC, Cmax) during combination therapy for sorafenib and sirolimus</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to evaluate efficacy of the combination descriptively (response rate and rate of stable diseases)</measure>
  </secondary_outcome>
  <condition>Advanced Solid Tumor</condition>
  <condition>Refractory to Standard Therapies</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histological or cytological confirmed advanced solid tumor, which is&#xD;
             refractory to standard therapies or for which no standard therapy exists and for which&#xD;
             there is a rationale for the therapeutic use of a combination of sorafenib and&#xD;
             sirolimus (especially metastic RCC, malignant melanoma, HCC, NSCLC, pancreatic cancer,&#xD;
             hormone refractory prostate cancer).&#xD;
&#xD;
          -  Men or women of at least 18 years&#xD;
&#xD;
          -  Patients who have an ECOG status of 0 or 1&#xD;
&#xD;
          -  Patients who have a life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function&#xD;
&#xD;
          -  Negative pregnancy test for female patients of childbearing potential&#xD;
&#xD;
          -  Women and men enrolled into this trial must use adequate birth control measures during&#xD;
             the course of the trial.&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of serious cardiac disease&#xD;
&#xD;
          -  Active clinically serious bacterial, viral or fungal infections (&gt; grade 2).&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) infection or chronic hepatitis B&#xD;
             or C.&#xD;
&#xD;
          -  Clinically symptomatic brain or meningeal metastasis.&#xD;
&#xD;
          -  Patients with seizure disorders requiring medication (such as steroids or&#xD;
             antiepileptics).&#xD;
&#xD;
          -  Patients with evidence or history of bleeding diathesis.&#xD;
&#xD;
          -  Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the patients participation in the study or evaluation of the study results.&#xD;
&#xD;
          -  Concomitant treatment with strong CYP3A4 inductors (such as rifampicin, St. JohnÂ´s&#xD;
             Wort) or CYP3A4 inhibitors (such as ketoconazole, voriconazole, itraconazole,&#xD;
             diltiazem, verapamil, erythromycin). Moderate or weak CYP3A4 modifiers should be used&#xD;
             concomitantly only after careful assessment of risk-benefit ratio. Concomitant use of&#xD;
             carbamazepine, phenobarbital, phenytoin or chronic use of dexamethasone is excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C.M.L. van Herpen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC St Radboud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMC St Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>July 30, 2007</study_first_submitted>
  <study_first_submitted_qc>July 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2007</study_first_posted>
  <last_update_submitted>September 17, 2009</last_update_submitted>
  <last_update_submitted_qc>September 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>C.M.L. van Herpen</name_title>
    <organization>University Medical Centre Nijmegen, st Radboud</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

